---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013583"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-04-20T23:59:59+00:00"
generated_at: "2026-06-16T23:07:39.012080+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics announces commercial leadership changes: Poyhonen, Mathews depart; Grillot appointed VP

## Summary
- John Poyhonen ceases as President and Chief Commercial Officer effective April 30, 2023.
- Michael Mathews ceases as SVP Commercial, Acute Care effective April 30, 2023.
- Jason Grillot appointed VP Sales and Marketing, Acute Care effective April 24, 2023.
- Grillot granted 350,000 stock options with 4-year vesting as material inducement.
- CEO Craig Collard will oversee commercial organization after departures.

## SEC filing metadata
- accession: 0000950170-23-013583
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-04-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/hrtx-20230418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013583
- JSON: https://secwatch.observer/filing/0000950170-23-013583.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013583.txt

## Key facts
- Executive change
  Michael Mathews departed as Senior Vice President Commercial, Acute Care at HERON THERAPEUTICS, INC. /DE/.
  - Action: cease to serve
  - Role: Senior Vice President Commercial, Acute Care
  source text: Also effective April 30, 2023, Michael Mathews will cease to serve as the Senior Vice President Commercial, Acute Care of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm
- Executive change
  Jason Grillot was appointed as Vice President, Sales and Marketing, Acute Care at HERON THERAPEUTICS, INC. /DE/.
  - Action: join
  - Role: Vice President, Sales and Marketing, Acute Care
  source text: Additionally, effective April 24, 2023, Jason Grillot will join the Company as Vice President, Sales and Marketing, Acute Care.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm
- Executive change
  John Poyhonen departed as President and Chief Commercial Officer at HERON THERAPEUTICS, INC. /DE/.
  - Action: cease to serve
  - Role: President and Chief Commercial Officer
  source text: Effective as of April 30, 2023, John Poyhonen will cease to serve as the President and Chief Commercial Officer of Heron Therapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.